FIELD: immunology.
SUBSTANCE: disclosed is a CD19-specific chimeric antigen receptor. Also, a polynucleotide, an expression vector created by genetic engineering of T-lymphocytes are considered. What is also described is a method for creating T-lymphocyte, methods of treating B-cell lymphoma or leukemia.
EFFECT: present invention can find further application in therapy of B-cell lymphoma and leukemia.
26 cl, 6 dwg, 1 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES TO CHIMERIC ANTIGEN RECEPTORS DERIVED FROM 4G7 | 2020 |
|
RU2826051C2 |
| RITUXIMAB-RESISTANT CHIMERIC ANTIGEN RECEPTORS AND WAYS OF USE THEREOF | 2020 |
|
RU2816370C2 |
| CELL | 2014 |
|
RU2717984C2 |
| CELL | 2014 |
|
RU2732236C2 |
| CELL | 2015 |
|
RU2768019C2 |
| CD20 THERAPY, CD22 THERAPY AND COMBINATION THERAPY WITH CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR (CAR) K CD19 | 2016 |
|
RU2752918C2 |
| CHIMERIC ANTIGEN RECEPTORS TARGETING HER2 | 2016 |
|
RU2753695C2 |
| CHIMERIC ANTIGEN RECEPTORS | 2015 |
|
RU2745705C2 |
| T- CELLS WITH COSTIMULATING CHIMERIC ANTIGEN RECEPTOR TARGETING IL13Rα2 | 2015 |
|
RU2749922C2 |
| TYPES OF COMBINATION THERAPY USING CHIMERIC ANTIGEN RECEPTORS AND PD-1 INHIBITORS | 2017 |
|
RU2809160C2 |
